IPM Take
AI in genomics is being sold as the next engine of precision medicine. That may be true. AI can help interpret variants, connect genomic and clinical data, support drug discovery, and make large-scale sequencing more usable. But market growth is not the same as health impact. The sector is expanding faster than many health systems can govern it, validate it, reimburse it or explain it to patients. The danger is a familiar one: the richest datasets, strongest compute infrastructure and clearest regulatory pathways may sit in the same places already leading precision medicine, while underrepresented populations become training-data afterthoughts.
Executive Summary
A Research and Markets report announced in June 2026 projects that the global AI in genomics market will grow from USD 2.18 billion in 2026 to USD 9.32 billion by 2030, with a reported compound annual growth rate of 43.7%. The report links this growth to the wider adoption of precision medicine, AI-powered drug discovery, deep learning genomic models, cloud-based data processing, machine learning for variant detection and integration of AI into genome sequencing and gene editing workflows.
The market signal is important, but it should be read cautiously. This is an industry forecast, not clinical evidence. It tells us where investment and commercial interest are moving. It does not prove that AI genomics tools improve patient outcomes, reduce diagnostic delay, or close access gaps.
The policy landscape is already tightening. In the EU, AI-based software intended for medical purposes can be treated as high-risk under the AI Act, requiring risk mitigation, high-quality datasets, clear user information and human oversight. The European Health Data Space and the 1+ Million Genomes initiative are also shaping how health and genomic data may be accessed, reused and governed. In the US, FDA has issued guidance on predetermined change control plans for AI-enabled devices and maintains a public list of AI-enabled medical devices. WHO has called for equitable access to genomics globally, warning that genomics must not become another technology divide.
The policy challenge is clear: AI genomics needs more than investment. It needs clinical validation, representative datasets, transparent governance, reimbursement pathways, patient consent models, cybersecurity protection and global equity safeguards.
Why it matters
- Policymakers and regulators: AI genomics will sit at the intersection of medical devices, diagnostics, medicines regulation, health data law and AI governance. Fragmented oversight could leave gaps in safety, accountability and patient protection.
- HTA bodies and payers: The value question is not whether AI can analyse genomes faster. It is whether it changes diagnosis, treatment selection, trial matching, prevention or outcomes enough to justify coverage.
- Clinicians and providers: AI-generated variant interpretation or genomic risk scoring must be clinically explainable, auditable and integrated into care pathways. A black-box genomic result is not precision medicine.
- Patients and advocates: Genomic data are uniquely sensitive. They can reveal information about relatives, ancestry and future risk. Patients need consent models that are understandable, not buried in technical language.
- Industry and innovation partners: The companies that win this market will not only be those with the best algorithms. They will be those that can demonstrate safety, fairness, interoperability and real-world clinical utility.
AI in genomics is being packaged as the next great precision medicine boom.
A new Research and Markets report projects that the global AI in genomics market will reach USD 9.32 billion by 2030, up from USD 2.18 billion in 2026. The drivers are obvious: cheaper sequencing, larger genomic datasets, cloud computing, machine learning for variant detection, AI-enabled drug discovery and growing demand for personalised healthcare.
That is the investment story.
The health policy story is more complicated.
Genomics has always promised to make medicine more precise. AI could make that promise more operational. It can help sift through enormous genomic datasets, identify disease-associated variants, prioritise drug targets, match patients to trials, support rare disease diagnosis and combine genomic data with imaging, laboratory results and electronic health records.
But the sector’s growth should not be confused with clinical readiness.
A market forecast tells us where capital is moving. It does not tell us whether patients benefit, whether models generalise across populations, whether clinicians understand the outputs, whether payers will reimburse the tools, or whether health systems can govern the data responsibly.
That distinction matters because genomic data are not ordinary health data.
They are deeply personal, but not only personal. A person’s genome can reveal information about relatives. It can point to inherited disease risk, ancestry, reproductive implications and future health vulnerability. It can also be reused repeatedly for research, drug discovery, commercial development and algorithm training.
That makes AI genomics politically sensitive from the start.
The first policy challenge is data representation. Genomics has a long diversity problem. Many datasets still overrepresent people of European ancestry, while African, Indigenous, Latin American, Middle Eastern, South Asian and other populations remain underrepresented. If AI models are trained on biased genomic datasets, they may work best for the populations already best represented in research and worst for those already underserved.
That is not a technical inconvenience. It is a health equity risk.
A variant interpretation tool that performs poorly in underrepresented populations can produce uncertainty, missed diagnoses or false reassurance. A polygenic risk score trained mainly on European ancestry data may not transfer reliably to other groups. An AI drug discovery platform may miss biology that is more visible in diverse datasets. The result is not neutral. It can hard-code historical exclusion into future care.
The second challenge is clinical validation.
AI genomics tools can look impressive in research settings. But clinical use requires more than accuracy metrics. Regulators, HTA bodies and clinicians need to know the intended use, target population, comparator, error profile, explainability, failure modes and downstream consequences. Does the tool reduce diagnostic odysseys in rare disease? Does it improve cancer therapy selection? Does it change prescribing? Does it increase appropriate trial matching? Does it reduce harm?
Without those answers, AI genomics risks producing faster interpretation without better care.
The third challenge is governance.
Europe is already building a dense policy architecture. The AI Act entered into force in 2024, and AI-based software intended for medical purposes can be treated as high-risk, with obligations around risk management, data quality, transparency and human oversight. The European Health Data Space creates a common framework for health data access and reuse. The 1+ Million Genomes initiative aims to enable secure access to genomic and clinical data across Europe to support research, health policy and personalised care.
This could make Europe a serious AI genomics governance laboratory.
But it will only work if regulation and implementation meet in the middle. Too little governance risks unsafe or biased tools. Too much friction risks trapping genomic innovation inside well-funded pilots that never reach routine care. The hard task is to build trust without freezing progress.
The United States is moving through a different route. FDA has been developing approaches for AI-enabled device software, including predetermined change control plans that allow some pre-specified model modifications while maintaining safety and effectiveness. FDA also maintains a public list of AI-enabled medical devices authorised for marketing. For genomics, this matters because AI tools may appear as clinical decision support, diagnostic software, variant interpretation systems, companion diagnostic support, trial-matching tools or drug development platforms.
The regulatory question is not only whether an AI tool works on day one. It is whether it remains safe after data drift, model updates, population shifts and new clinical use cases.
The UK offers another important model. Genomics England’s Generation Study is sequencing 100,000 newborns to evaluate whether whole genome sequencing can improve diagnosis and treatment of rare genetic conditions. It is not only a genomics project. It is a public trust experiment. It tests whether a national health system can use genomic data at scale while maintaining consent, transparency, clinical utility and public confidence.
That trust will be essential everywhere.
AI genomics also raises the question of who captures value. The market report lists major technology, AI, biotech and genomics companies. That is expected. The commercial opportunity is real. But public health systems and citizens are also generating the data that make this market valuable. If public genomic datasets fuel private tools, then public return must be part of the bargain.
That return could include affordable diagnostics, transparent algorithms, local data access, benefit-sharing, public-sector capacity building and commitments to serve underrepresented populations.
Otherwise, AI genomics becomes extraction with better branding.
The global dimension is even sharper. WHO has called for equitable access to genomics, especially so that low-resource countries are not excluded from the benefits of genomic medicine. That warning should now be applied directly to AI. Countries without sequencing infrastructure, cloud capacity, trained genomic workforce, regulatory systems or reimbursement pathways may become consumers of imported AI tools trained on other populations.
That is not precision medicine. It is dependency.
Asia-Pacific is identified in the market report as the fastest-growing region. That growth could be transformative, especially as countries expand national genomics programmes, biotech capacity and digital health infrastructure. But rapid growth also demands stronger safeguards: data localisation rules, cross-border data governance, cybersecurity, informed consent, local validation and clinical workforce training.
Genomics cannot be scaled like ordinary software.
The stakes are too high. A wrong search result is annoying. A wrong genomic interpretation can change treatment, family planning, surveillance, insurance anxiety or years of clinical follow-up. A breach of genomic data cannot simply be reset with a new password.
That is why AI genomics should be evaluated as health infrastructure, not just a technology category.
Health systems need clear rules. What counts as clinical-grade AI genomic interpretation? When does software become a medical device? Who is liable for an incorrect variant classification? How are model updates monitored? How are patients informed when their genomic data are used to improve algorithms? How are minority populations protected from both exclusion and exploitation?
The answer cannot be left to the market alone.
The AI genomics boom may be real. It may accelerate drug discovery. It may shorten diagnostic odysseys. It may improve personalised oncology, rare disease care and pharmacogenomics. It may help clinicians interpret data that would otherwise be unusable.
But the future is not guaranteed.
AI will not automatically democratise genomics. Without deliberate policy, it could concentrate power in the hands of companies and countries with the largest datasets, the strongest compute capacity and the most permissive access to patient data.
Precision medicine was supposed to move healthcare beyond one-size-fits-all. AI genomics could help achieve that.
Or it could create a new form of one-size-fits-some.
